Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BCG solution + mRNA-4157 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BCG solution | TICE BCG solution | Bacillus Calmette-Guerin solution | TICE BCG solution (BCG solution) is an attenuated live culture of Bacillus Calmette Guerin that induces anti-tumor immunity in bladder cancer (PMID: 26000263). TICE BCG solution (BCG solution) is FDA approved for carcinoma in situ of the bladder (FDA.gov). | |
mRNA-4157 | mRNA4157|mRNA 4157|V940|V-940|V 940 | mRNA-4157 is an mRNA-based lipid encapsulated personalized cancer vaccine encoding specific neoantigens, which potentially leads to enhanced anti-tumor immune response (Journal for ImmunoTherapy of Cancer 2020;8). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06833073 | Phase II | mRNA-4157 BCG solution + mRNA-4157 BCG solution | A Clinical Study of V940 and BCG in People With Bladder Cancer (V940-011/INTerpath-011) | Recruiting | USA | ITA | AUS | 0 |